INFORM2: An exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with high risk Malignancies

Project Overview

The INFORM2 (INdividualized Therapy for Relapsed Malignancies in Childhood) trial is for children and adolescents dealing with high-risk solid tumors and central nervous system tumors that have relapsed, are refractory, or are progressing.

In collaboration with the German Cancer Research Centre (DKFZ) in Heidelberg, Germany, the INFORM2 trial, which is conducted in multiple European Innovative Therapies for Children with Cancer Centers (ITCC), is also available in Australia through the Zero Childhood Cancer Program (ZERO). This partnership, combined with ZERO’s molecular screening platform for eligibility assessment, provides Australian children with access to Nivolumab and Entinostat combination therapy as part of this multinational phase I/II clinical trial.

Anticipated as the first of many such trials in Australia, INFORM2 will reduce the financial and emotional burdens on families by eliminating the need to travel abroad for participation and access to these therapies.

The Luminesce Alliance, supported by the Brain Cancer Mission, has played a pivotal role in funding the INFORM2 trial.


  • Kids Cancer Centre, Sydney Children’s Hospital Randwick (Australia)
  • The German Cancer Research Center (DKFZ) (Germany)
  • Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ) (Germany)
  • Children’s Cancer Institute (Australia)
  • The Zero Childhood Cancer Program, National and International Partners (Australia)
  • University of New South Wales Sydney (Australia)
  • Consumer representative groups

The INFORM2 trial is granting eligible Australian children with brain cancer access to innovative clinical trials, aiming to enhance survival rates and long-term outcomes.

Lead Investigators

  • David Ziegler - 328x328@2x

    Associate Professor David Ziegler

    Head, Clinical Trials Program, Kids Cancer Centre, Sydney Children’s Hospital Randwick and Group Leader, Targeted Therapy Group, Children’s Cancer Institute
  • Professor Olaf Witt

    Director Translational Pediatric Oncology Hopp Children's Cancer Center Heidelberg
  • Vanessa Tyrrell

    Personalised Medicine Program Leader, Children’s Cancer Institute